RxDoctor Payments Data

Scott Marsh, DPM

Foot & Ankle Surgery · Logansport, INNPI 1679762827

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $34,340 of the $40,700 with a category attached, or 84.4%. Medical Device Business Services, Inc. accounts for 67.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $15,035 and has fallen 96.7% since, to $499 in 2025. Among foot & ankle surgery clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,700in general payments, 2019–2025

Across 75 payments — averaging $542.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$27K
  • Prosidyan, Inc$6K
  • Johnson & Johnson$4K
  • Depuy Synthes Products, Inc.$2K
  • Stryker$560
  • CDC Medical LLC$511
  • plus $263 from 7 others

What the payments were for

  • Consulting fees$34,34084%
  • Travel & lodging$2,9257%
  • Food & beverage$2,9247%
  • Education$5111%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,700 in reported general payments places this provider in the 90th percentile of 212 foot & ankle surgery providers in Indiana.

See all foot & ankle surgery providers in Indiana

Medicare billing

Part B allowed, 2024
$78,780
Medicare patients
466
Services billed
1,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.11$3,465
Ciclopirox61$1,909
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen76$538
Ammonium Lactate53$520
Cephalexin67$421
Terbinafine Hcl51$376
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$342
Gabapentin26$309
Clindamycin Hcl34$251
Methylprednisolone29$172
Mupirocin25$137
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$137
Meloxicam51$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$44$3,46511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 212 foot & ankle surgery providers in Indiana.

Other foot & ankle surgery in Logansport

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →